RxDoctor Payments Data

Joseph Pettus, MD

Urology · Huntsville, ALNPI 1083807333

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,015 of the $7,078 with a category attached, or 85.0%. 44 manufacturers reported payments, led by Coloplast at 31.1% of the total. Reporting peaked in 2019 at $2,371 and has fallen 65.7% since, to $814 in 2025.

$7,078in general payments, 2019–2025

Across 275 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$2K
  • Medtronic$849
  • Axonics, Inc.$411
  • Astellas Pharma US Inc$409
  • Myriad Genetic Laboratories, Inc.$359
  • AbbVie$348
  • plus $3K from 38 others

What the payments were for

  • Travel & lodging$86512%
  • Food & beverage$6,01585%
  • Education$1092%
  • Entertainment$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,078 in reported general payments places this provider in the 75th percentile of 179 urology providers in Alabama.

See all urology providers in Alabama

Medicare billing

Part B allowed, 2024
$390,306
Medicare patients
791
Services billed
6,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron52$37,173
GemtesaVibegron21$21,579
ElmironPentosan Polysulfate Sodium11$12,934
Testosterone35$11,351
Tamsulosin Hcl419$6,537
Tolterodine Tartrate ErTolterodine Tartrate18$4,797
Solifenacin Succinate85$3,953
Testosterone Cypionate61$3,118
Estradiol29$2,217
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst43$984
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen150$799
Alfuzosin Hcl ErAlfuzosin Hcl37$708
Finasteride38$573
Ciprofloxacin Hcl102$282
Doxycycline Hyclate23$242

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$409$37,17352 claims
Sumitomo Pharma America, Inc.Gemtesa$44$21,57921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 179 urology providers in Alabama.

Other urology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →